Grieder, S. | bioRxiv Science

bioRxiv2025

The glutamine-aspartate metabolic tradeoff between fast growth and metabolic flexibility.

Cancer cells develop unique addictions to nutrients, offering attractive opportunities for clinical intervention. However, how cancer cells orchestrate and benefit from metabolic rewiring remain fundamental open questions. Here, we developed a systematic framework to investigate nutrient dependencies and applied it to study glutamine addiction. By measuring metabolite exchange rates across 54 cancer cell lines with different levels of dependency on extracellular glutamine and in human stem cells, we discovered that a dualistic regulation of glutamate biosynthesis from glutamine or aspartate, driven by the tissue of origin, generates a tradeoff between fast growth and metabolic flexibility. Monitoring dynamic metabolic adaptation to glutamine deprivation showed that the role of glutamine as limiting substrate in purine biosynthesis is not responsible for glutamine dependency. Rather, growth arrest is mediated by glutamine as a signaling molecule. Our approach opens new opportunities to map, mechanistically investigate and pharmacologically interfere with metabolic dependencies, beyond glutamine addiction.

cancer biology↗

bioRxiv2020

Cross-Platform Validation of Neurotransmitter Release Impairments in Schizophrenia Patient-Derived NRXN1-Mutant Neurons

Heterozygous NRXN1 deletions constitute the most prevalent currently known single-gene mutation predisposing to schizophrenia. Previous studies showed that engineered heterozygous NRXN1 deletions impaired neurotransmitter release in human neurons, suggesting a synaptic pathophysiological mechanism. Utilizing this observation for drug discovery, however, requires confidence in its robustness and validity. Here, we describe a multi-center effort to test the generality of this pivotal observation, using independent analyses at two laboratories of patient-derived and newly engineered human neurons with heterozygous NRXN1 deletions. We show that in neurons that were trans-differentiated from induced pluripotent stem cells derived from three NRXN1-deletion patients, the same impairment in neurotransmitter release was observed as in engineered NRXN1-deficient neurons. This impairment manifested as a decrease in spontaneous synaptic events and in evoked synaptic responses, and an alteration in synaptic paired-pulse depression. Nrxn1-deficient mouse neurons generated from embryonic stem cells by the same method as human neurons did not exhibit impaired neurotransmitter release, suggesting a human-specific phenotype. NRXN1 deletions produced a reproducible increase in the levels of CASK, an intracellular NRXN1-binding protein, and were associated with characteristic gene expression changes. Thus, heterozygous NRXN1 deletions robustly impair synaptic function in human neurons regardless of genetic background, enabling future drug discovery efforts.

neuroscience↗